Can a promising NAFLD drug safely mix with other medicines? a trial seeks answers
Disease control
Not yet recruiting
This trial investigates whether ECC4703, a potential new treatment for non-alcoholic fatty liver disease (NAFLD), changes how the body processes two other drugs: sulfasalazine and pitavastatin. Healthy adults aged 18 to 65 will take these drugs alone and then with ECC4703 to meas…
Phase: PHASE1 • Sponsor: Eccogene • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC